Earnings History Data for IDEAYA Biosciences, Inc. (IDYA) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

IDEAYA Biosciences, Inc.

IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences Inc. is based in South San Francisco, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
04-11-2024	PM		IDYA	IDEAYA Biosciences	2,378	-0.60	-0.67	0.00	IDEAYA Biosciences GAAP EPS of -$0.60 beats by $0.04 [11/4/2024 6:13 AM]	30.07	1.47 (5.14%)	28.60	0.0 (0.00%)	27.52 - 47.74	855,754	690,000	15,850
IDEAYA Biosciences GAAP EPS of -$0.60 beats by $0.04 [11/4/2024 6:13 AM]
06-08-2024	PM		IDYA	IDEAYA Biosciences	3,034	-0.68	-0.55	0.00		36.00	-0.99 (-2.68%)	0.0	0.0 (0.00%)	21.24 - 47.74	785,518	760,000	0

07-05-2024	PM		IDYA	IDEAYA Biosciences	3,154	-0.53	-0.53	0.00	IDEAYA Biosciences GAAP EPS of -$0.53 misses by $0.01 [5/7/2024 6:06 AM]	42.72	-0.37 (-0.86%)	0.0	0.0 (0.00%)	18.96 - 47.74	812,066	700,000	0
IDEAYA Biosciences GAAP EPS of -$0.53 misses by $0.01 [5/7/2024 6:06 AM]
20-02-2024	PM		IDYA	IDEAYA Biosciences	3,038	-0.52	-0.49	0.00	IDEAYA Biosciences GAAP EPS of -$0.52, revenue of $3.9M [2/20/2024 9:52 AM]	43.93	-3.20 (-6.79%)	47.72	0.59 (1.25%)	13.29 - 47.74	559,506	800,000	410
IDEAYA Biosciences GAAP EPS of -$0.52, revenue of $3.9M [2/20/2024 9:52 AM]
07-11-2023	PM		IDYA	IDEAYA Biosciences	1,667	-0.46	-0.47	0.00	IDEAYA Biosciences GAAP EPS of -$0.46 beats by $0.05, revenue of $8.04M beats by $0.71M [11/7/2023 6:28 AM]	29.27	0.34 (1.16%)	29.43	0.50 (1.73%)	13.29 - 30.33	581,788	1,230,000	208
IDEAYA Biosciences GAAP EPS of -$0.46 beats by $0.05, revenue of $8.04M beats by $0.71M [11/7/2023 6:28 AM]
10-08-2023	PM		IDYA	IDEAYA Biosciences	1,240	-0.50	-0.53	0.00	IDEAYA Biosciences GAAP EPS of -$0.50 beats by $0.06, revenue of $3.54M misses by $0.86M [8/10/2023 10:54 AM]	25.43	0.62 (2.50%)	24.30	-0.51 (-2.06%)	9.00 - 26.35	681,039	520,000	501
IDEAYA Biosciences GAAP EPS of -$0.50 beats by $0.06, revenue of $3.54M misses by $0.86M [8/10/2023 10:54 AM]
07-03-2023	PM	6:00 AM ET (Mar 7)	IDYA	IDEAYA Biosciences	831.00	-0.50	-0.57	0.00	IDEAYA Biosciences GAAP EPS of -$0.50 beats by $0.06, revenue of $4.02M misses by $2.98M [3/7/2023 6:17 AM]	17.91	1.05 (6.23%)	0.0	0.0 (0.00%)	8.14 - 19.14	270,785	220,000	0
IDEAYA Biosciences GAAP EPS of -$0.50 beats by $0.06, revenue of $4.02M misses by $2.98M [3/7/2023 6:17 AM]
08-11-2022	PM		IDYA	IDEAYA Biosciences	671.00	0.04	-0.65	0.00	IDEAYA Biosciences GAAP EPS of $0.04 beats by $0.66, revenue of $29.7M beats by $23.06M [11/8/2022 9:16 AM]	18.05	0.47 (2.67%)	18.19	0.61 (3.47%)	8.14 - 24.71	851,423	380,000	947
IDEAYA Biosciences GAAP EPS of $0.04 beats by $0.66, revenue of $29.7M beats by $23.06M [11/8/2022 9:16 AM] IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings and Revenues Beat Estimates [Nov-08-22 07:35AM] IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update [Nov-08-22 06:00AM]
15-08-2022	PM	6:00 AM ET (Aug 15)	IDYA	IDEAYA Biosciences	577.00	-0.57	-0.57	0.00	IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M [8/15/2022 6:19 AM]	10.20	-5.45 (-34.86%)	14.17	-1.48 (-9.46%)	8.14 - 28.00	2,165,414	200,000	2,158
IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M [8/15/2022 6:19 AM] Ideaya sheds 34% as GSK waives option for cancer candidate [8/15/2022 10:14 AM] IDEAYA downgraded to hold at Stifel after GSK waives development of cancer candidate [8/15/2022 11:49 AM]
10-05-2022	PM		IDYA	IDEAYA Biosciences, Inc.	372.03	-0.36	-0.41	-0.28	IDEAYA Biosciences GAAP EPS of -$0.36 beats by $0.06, revenue of $11.36M beats by $5.03M [5/10/2022 6:26 AM]	9.28	1.00 (12.08%)	8.54	0.26 (3.14%)	8.14 - 28.00	194,651	388,815	402
IDEAYA Biosciences GAAP EPS of -$0.36 beats by $0.06, revenue of $11.36M beats by $5.03M [5/10/2022 6:26 AM] We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate [May-06-22 09:59AM] IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update [May-10-22 06:00AM] IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Tops Revenue Estimates [May-10-22 07:15AM]
15-03-2022	PM		IDYA	IDEAYA Biosciences	516.00	-0.47	-0.31	0.00	IDEAYA Biosciences GAAP EPS of -$0.47 misses by $0.16, revenue of $2.96M misses by $6.02M [3/15/2022 6:02 AM]	13.36	0.57 (4.46%)	14.00	1.83 (15.04%)	11.75 - 28.00	92,474	370,708	7,616
Ideaya, Pfizer ink study pacts for darovasertib/crizotinib combo for eye, liver cancers [3/14/2022 6:30 AM] IDEAYA Biosciences GAAP EPS of -$0.47 misses by $0.16, revenue of $2.96M misses by $6.02M [3/15/2022 6:02 AM] IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors [Mar-14-22 06:00AM] IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data [Mar-15-22 05:55AM] IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update [Mar-15-22 06:00AM] IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates [Mar-15-22 07:15AM] Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial [Mar-15-22 08:48AM]
15-11-2021	PM		IDYA	IDEAYA Biosciences	866.00	-0.31	-0.29	0.00	IDEAYA Biosciences EPS beats by $0.01, beats on revenue [11/15/2021 6:12 AM]	23.40	0.37 (1.61%)	23.03	0.0 (0.00%)	12.28 - 28.00	286,782	210,000	3,565
IDEAYA Biosciences EPS beats by $0.01, beats on revenue [11/15/2021 6:12 AM] IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update [Nov-15-21 06:01AM] What Kind Of Shareholders Hold The Majority In IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) Shares? [Nov-15-21 08:44AM]
10-08-2021	PM	6:00 AM ET (Aug 10)	IDYA	Ideaya Biosciences, Inc.	762.00	-0.33	-0.07	0.00	IDEAYA Biosciences EPS misses by $0.24, misses on revenue [8/10/2021 6:17 AM]	22.83	-0.37 (-1.59%)	0.0	0.0 (0.00%)	11.00 - 26.00	246,205	290,000	0
IDEAYA Biosciences EPS misses by $0.24, misses on revenue [8/10/2021 6:17 AM] IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update [Aug-10-21 06:00AM] IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates [Aug-10-21 07:15AM]
10-05-2021	PM		IDYA	Ideaya Biosciences, Inc.	625.00	-0.28	-0.28	0.00	IDEAYA Biosciences EPS beats by $0.01, misses on revenue [5/10/2021 6:13 AM]	19.47	0.29 (1.51%)	19.18	0.0 (0.00%)	6.08 - 24.92	116,921	150,000	119
IDEAYA Biosciences EPS beats by $0.01, misses on revenue [5/10/2021 6:13 AM] IDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update [May-10-21 06:00AM] IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort [May-10-21 06:00AM] IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates [May-10-21 07:30AM]
23-03-2021	PM	6:00 AM ET (Mar 23)	IDYA	IDEAYA Biosciences, Inc.	726.62	-0.18	-0.24	-0.53	IDEAYA Biosciences EPS beats by $0.04, beats on revenue [3/23/2021 6:31 AM]	22.90	-0.35 (-1.51%)	23.25	0.0 (0.00%)	3.20 - 24.53	200,377	240,000	3,747
IDEAYA Biosciences EPS beats by $0.04, beats on revenue [3/23/2021 6:31 AM] IDEAYA announces dose expansion of Phase 1/2 study on metastatic uveal melanoma [3/23/2021 8:46 AM] IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update [Mar-23-21 06:05AM] IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity [Mar-23-21 06:05AM] IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Lags Revenue Estimates [Mar-23-21 07:30AM] IDEAYA Posts Better-Than-Feared Quarterly Loss, Sales Top Estimates [Mar-23-21 10:24AM]
12-11-2020	PM		IDYA	IDEAYA Biosciences, Inc.	399.43	-0.17	1.34	-0.54	IDEAYA Biosciences reports Q3 results [11/12/2020 6:17 AM]	13.03	-1.17 (-8.24%)	13.03	0.0 (0.00%)	2.95 - 19.97	927,779	243,504	3,021